IDRA 21

• Description:

  IDRA 21 is a positive and orally active modulator of the AMPA receptor. IDRA 21 facilitates excitatory neurotransmission via GluR1/2 receptors. IDRA 21 has the potential for the research of cognitive/memory disorders, including those associated with aging[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  IGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel; Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/idra-21.html

• Purity:

  99.66

• Solubility:

  DMSO : 250 mg/mL (ultrasonic)

• Smiles:

  CC(NC1=CC=C(Cl)C=C12)NS2(=O)=O

• Molecular Formula:

  C8H9ClN2O2S

• Molecular Weight:

  232.69

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Buccafusco JJ, et al. The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys. Neuropharmacology. 2004 Jan;46 (1) :10-22. doi: 10.1016/j.neuropharm.2003.07.002.|[2]Yamada KA, et al. The diazoxide derivative IDRA 21 enhances ischemic hippocampal neuron injury. Ann Neurol. 1998 May;43 (5) :664-9.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  AMPA Receptor

• CAS Number:

  [22503-72-6]